Asp Isotopes INC 8-K filings

ASP Isotopes Inc. announced its subsidiary, Tetra4 Proprietary Limited, has entered into a new five-year take-or-pay contract for the sale of liquified natural gas (LNG) from the Virginia Gas Project.

ASP Isotopes Inc. announced its participation in Citi's 2026 Natural Resources Conference, including investor meetings to discuss its advanced materials and isotope enrichment technologies.

ASP Isotopes Inc. provides a comprehensive shareholder update detailing progress in PET Labs, Renergen's helium production, and advancements in stable isotope enrichment, alongside strategic corporate developments.

ASP Isotopes Inc. announced its participation in Canaccord Genuitys 46th Annual Growth Conference on August 12, 2026, where Chief Commercial Officer Viktor Petkov will deliver a presentation.

ASP Isotopes Inc. will host a Capital Markets Day in London on September 8, 2026, to provide updates on strategic direction and commercial momentum.

ASP Isotopes Inc. announces a research agreement with Texas A&M Engineering Experiment Station to advance and de-risk the commercial production of high-purity uranium hexafluoride (UF6).

ASP Isotopes Inc. is filing a Form 8-K to retrospectively recast certain financial information from its 2025 Annual Report to present its construction services business as discontinued operations.

ASP Isotopes Inc. announced agreements to exchange approximately $109.2 million of QLE convertible notes for new shares of ASPI common stock, reducing QLE's debt by about 50% as it pursues a separate public listing.

ASP Isotopes' subsidiary Noble Africa will merge with ENDRA Life Sciences, creating a Nasdaq-listed helium platform with a concurrent $50 million private placement.

ASP Isotopes will merge its subsidiary Noble Africa with ENDRA Life Sciences in a transaction accompanied by a $50 million private placement.

ASP Isotopes Inc. has successfully restarted the first 18 stages of its Silicon-28 enrichment facility and expects to commence commercial shipments in Q3 2026.

ASP Isotopes Inc. has published an updated investor presentation on its corporate website as of May 20, 2026.

ASP Isotopes Inc. announces its subsidiary, Quantum Leap Energy LLC, has entered into a Memorandum of Understanding with a European nuclear technology company for the potential supply of High Assay Low Enriched Uranium (HALEU).

ASP Isotopes Inc. announced that its subsidiary, Quantum Leap Energy LLC, has appointed Dr. Peter S. Fiske to its Strategic Advisory Board to enhance government partnerships and advanced materials strategy.

ASP Isotopes Inc. announced significant operational progress, expecting first commercial isotope shipments in 2026 and targeting Helium Phase 1 nameplate capacity in Q3 2026, alongside a 2031 EBITDA target exceeding $300 million.

ASP Isotopes Inc. announced a business update conference call and webcast scheduled for April 13, 2026, to discuss company progress.

ASP Isotopes Inc. filed an amended 8-K to include detailed financial statements and pro forma information for its recently completed acquisition of Renergen Limited.

ASP Isotopes' subsidiary, Quantum Leap Energy, is collaborating with the University of Bristol to design a state-of-the-art lithium laser research facility in the UK.

ASP Isotopes Inc. announced the completion of well drilling for Phase 1 of the Renergen Helium Project four months ahead of schedule, significantly reducing execution risk.

ASP Isotopes Inc.'s subsidiary, Quantum Leap Energy, signed a non-binding MOU with a major U.S. energy company to evaluate support for advancing the domestic enriched uranium fuel supply chain.

ASP Isotopes' subsidiary, Quantum Leap Energy, names Dr. Nate Salpeter, a renowned expert in fluid dynamics and energy technology, as its Chief Technology Officer.

ASP Isotopes' subsidiary, Quantum Leap Energy, signed a Pre-Implementation Services Contract Agreement with South African Nuclear Energy Corporation (Necsa) to advance High Assay Low Enriched Uranium (HALEU) production.

ASP Isotopes Inc.'s subsidiary, Quantum Leap Energy, has established a Strategic Advisory Board with two distinguished nuclear fuel and advanced materials leaders to guide its nuclear fuel cycle initiatives.

ASP Isotopes' subsidiary, Quantum Leap Energy, announced plans to establish its global corporate headquarters in Austin, Texas, to advance nuclear fuel cycle technologies.

ASP Isotopes Inc. has entered into a definitive agreement to acquire Series Seed-1 Preferred Stock in Opeongo, Inc., a biotechnology company focused on fibrosis, inflammation, and cancer therapeutics.

ASP Isotopes Inc. provides a production update on the Renergen Helium Project, highlighting significant operational improvements and a clear path to positive operational cash flow by late 2026.

ASP Isotopes Inc. announced the appointment of Stefano Marani as President, Electronics and Space, and Nick Mitchell as Co-Chief Operating Officer, following the acquisition of Renergen Limited.

ASP Isotopes has finalized its acquisition of Renergen, creating a combined entity focused on becoming a global critical materials provider in isotope and helium markets.

ASP Isotopes Inc. announced the results of its 2025 Annual Meeting of Stockholders, where two Class III Directors were elected and EisnerAmper LLP was ratified as the independent auditor.

ASP Isotopes Inc. confirmed the South African Takeover Regulation Panel issued a compliance certificate, allowing the Renergen Limited acquisition scheme to proceed.